Protalix Biotherapeutics, Inc. (de) · AMEX:PLX
Protalix Biotherapeutics, Inc. (de) — Investor Presentation (August 2026)
23 slides from Protalix Biotherapeutics, Inc. (de)'s investor presentation, August 2026
Slide 1: Protalix Biotherapeutics Corporate Presentation
PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases PROTALIX BIOTHERAPEUTICS CORPORATE PRESENTATION J uu ng eu s2t 0 22 04 2 6 A 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Third-Party Information This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the This presentation also contains estimates and Securities Act of 1933, as amended, or the Securities Act, and Section
Slide 3: Experienced leadership team
Experienced leadership team Dror Bashan YARON NAOS President and CEO Chief Operating Officer Mr. Bashan has over 20 years of experience in the Mr. Naos has been with Protalix for >20 years. He has a pharmaceutical industry with roles ranging from business wealth of hands-on experience and knowledge
Slide 4: Accomplished Board of Directors
Accomplished Board of Directors ELIOT FORSTER, PH.D. DROR BASHAN POL F. BOUDES, M.D. GWEN A. MELINCOFF Chairman President & CEO, Director Director Director AHARON SCHWARTZ, AMOS BAR SHALEV SHMUEL “MULI” BEN Christian Else PH.D. Director ZVI, PH.D. Director Director Director BATM logo 4
Slide 5: Protalix delivers innovations from concept to market
Protalix delivers innovations from concept to market Proven execution of delivering protein products for rare diseases with a pipeline for the future Revenue generating Next phase of the company Partnered commercial products PRX-115 best-in-class potential Pipeline for the future Enzyme replacement
Slide 6: Two commercial products and a growing pipeline for the future
Two commercial products and a growing pipeline for the future Developing recombinant proteins for rare diseases with unmet medical needs Discovery Marketing Indication Phase 1 Phase 2 Phase 3 Status and Preclinical Application Commercial portfolio Approved in the US, Fabry Disease European Union, an
Slide 7: Well-capitalized to advance Protalix to the next phase
Well-capitalized to advance Protalix to the next phase The Company achieved profitability with a net income of $22.1 million for the first half of 2026 Elfabrio® sales drove revenues from selling goods up to $19.8 million in the second quarter of 2026 REVENUES (+$4.4 million from Q2 2025); total rev
Slide 8: Key upcoming milestones and catalysts
Key upcoming milestones and catalysts Elfabrio® PRX-115 2 mg/kg IV Increasing market share Expanding Phase 2 PRX-115 trial Topline results every four weeks in current geographies geographic actively enrolling from Ph2 trial (EU) (organic growth) approvals March 2026 Ongoing Ongoing Q1 2026 2H 2027 C
Slide 9: PRX-115 in development for uncontrolled gout
Phase 2 Actively enrolling PRX-115 in development for uncontrolled gout 9
Slide 10: Uncontrolled gout: limited options and disadvantages with current therapy
Uncontrolled gout: limited options and disadvantages with current therapy An unsatisfied market Gout and uncontrolled gout • Metabolic disorder characterized by elevated blood urate that causes recurrent inflammatory arthritis and joint damage • Rheumatologists report that ~25% of their patients hav
Slide 11: The US Gout Market
The US Gout Market Gout Seek treatment Referred to Uncontrolled Qualify patients at PCP rheumatologists gout for uricase Krystexxa® 11.3M1 5M2 1.2M2 0.3M3 0.18M3 6-8K4 Uricase Treatments URAT1s**,† allopurinol, febuxostat† The market is poised to expand significantly A differentiated best-in-class u
Slide 12: PRX-115 Phase 1 single ascending dose study
PRX-115 Phase 1 single ascending dose study: encouraging data supports Phase 2 Recombinant PEGylated uricase enzyme produced via ProCellEx® Study Scheme Primary Endpoint: Safety and tolerability Cohort 8 Secondary Endpoints: PK, PD (uric acid levels) Cohort 7 Subjects with elevated uric acid Cohort
Slide 13: PRX-115 best in class potential for uncontrolled gout
PRX-115 best in class potential for uncontrolled gout Addresses an important unmet medical need PRX-115 Phase 1 outcome Phase 2 RELEASE study • Favorable tolerability profile • Actively enrolling (NCT07280156) • Ability to reduce uric acid levels rapidly and maintain below 6.0 mg/dL • Trial in uncon
Slide 14: PRX-115 Phase 2 double blind placebo-controlled study design
PRX-115 Phase 2 double blind placebo-controlled study design: actively enrolling Fixed Dose at Various Dosing Intervals Patient Population: uncontrolled gout PRX-115 IV Dosing Regimens and Treatment Arms Primary Endpoint: proportion of patients who achieve Arm A* every 4 weeks w/o MTX N=30 a reducti
Slide 15: Commercial products
Commercial products Reliably partnered and delivering revenue 15
Slide 16: Two commercial products sustaining future growth
Two commercial products sustaining future growth Enzyme replacement therapies (ERTs) continue to be the gold standard treatment for lysosomal storage diseases Fabry disease Gaucher disease Rare X-linked disorder (~1/40,000-60,000 males WW) with Rare autosomal recessive disorder (~1/40,000 WW) with p
Slide 17: EC and MHRA approve every-4-weeks Elfabrio dosing
EC and MHRA approve every-4-weeks (E4W) Elfabrio® dosing for adults with Fabry disease1 Now the only ERT in the EU offering an E4W option, reducing treatment burden from standard bi-weekly regimens Infusions per year Elfabrio® E4W dosing clinically validated BRIGHT study Quality-of-life • E4W mainta
Slide 18: Fabry disease competitive landscape
Fabry disease competitive landscape ~$2.2B market (2025) expected to reach over ~$3.2B (2031), CAGR of 6.4%1 Product Name Fabrazyme® Replagal® Galafold® Elfabrio® Parent Company ERT Mechanism ERT ERT Pharmacological chaperone longer half-life (pegylated) Adults & pediatric patients 2+ years Accelera
Slide 19: Commitment and execution from global partnership with Chiesi
Commitment and execution from global partnership with Chiesi Committed Global Partner 1 • International research-focused biopharmaceutical group with sales of €3.6B in 2025 (reflecting 8% growth year-on-year) • Air (respiratory) - €1.9B, Rare - €906M (22.3% growth), Care (Specialty) - €904M • The Ra
Slide 20: Growth strategy
Growth strategy Next phase of the company 20
Slide 21: Research strategy - leveraging internal strengths
Research strategy - leveraging internal strengths to fuel the company's next phase Proven ability to drive discovery, development, and registration of new drugs Rare renal disease focus 3-year goal • ADPKD, Alport, FSGS, others 5-7 programs spanning • Modality agnostic: nucleic acids, peptides, smal
Slide 22: Protalix delivers innovation from concept to the market
Protalix delivers innovation from concept to the market Two commercial products Three revenue streams Growing pipeline for the company's next phase • PRX-115 best-in-class potential for uncontrolled gout • Collaboration and Option Agreements • Internal research focus – Rare Renal Diseases Cash and S
Slide 23: Protalix Biotherapeutics
PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases PROTALIX BIOTHERAPEUTICS CORPORATE PRESENTATION J uu ng eu s2t 0 22 04 2 6 A 23
Protalix BioTherapeutics — Investor Presentation (August 2026) on 6ix